Real-world data show Lybalvi cuts acute care visits in schizophrenia or bipolar I with AUD, while long-acting aripiprazole offers flexible dosing and stable symptom control.
James McGrory, PhD
Advertisement
Articles by James McGrory, PhD
Real-world data highlights Lybalvi’s impact on acute care use in high-risk patients and Aristada’s long-acting dosing for steadier schizophrenia treatment.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
2
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
3
Adjustment Disorder Is Hiding in Plain Sight
4
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
5